



ASX Announcement

27 June 2025

Share Purchase Plan Results & Tranche 2 Placement Approved

SYDNEY Australia, 27 June 2025 – Atomo Diagnostics Limited (ASX: **AT1**) (**Atomo** or the **Company**) confirms that the Share Purchase Plan (“**SPP**”) announced to the ASX on 24 April 2025 closed 5pm Monday, 23 June 2025. The Company received valid applications for 14,723,685 shares raising \$272,387.50 (before costs) including director participation. The Directors have accepted all valid applications in full in accordance with the Prospectus dated 20 May 2025. The Applicants will also receive 14,723,685 free attaching options, exercisable at \$0.04 (4 cents), expiring on 27 June 2028 (“**Options**”).

Under the SPP, shareholders in the Company registered in Australia on the record date of 23 April 2025 (“**Eligible Shareholders**”) were entitled to subscribe for up to \$30,000 of new fully paid ordinary shares (“**SPP Shares**”) in the Company at the issue price of \$0.0185 (1.85 cents) per SPP Share. The Company reserves the right to place the SPP Shortfall which amounts to \$727,612.50.

The Company also confirms that it has received shareholder approval at its EGM held on 23 June 2025 to raise \$1,257,800 from the Tranche 2 Placement, announced on 24 April 2025, and will in due course issue 67,989,186 Shares, at an issue price of \$0.0185 (1.85 cents) per Share and 67,989,186 Options, to professional, sophisticated and other exempt investors, including a Director.

The Shares will rank equally with existing shares in the Company. The Placement and SPP Shares are to be issued today.

Managing Director & CEO & Interim Chair, John Kelly, commented:

“On behalf of the Board of Atomo Diagnostics Limited I wish to thank existing and new shareholders for their participation in the Company’s fund-raising initiatives via the Share Purchase Plan and Placement. With the raising complete and the Board refreshed the Company is in a strong position to move forward with its operational activities”.

~ ENDS ~

For more information, please contact:

John Kelly

Managing Director & CEO & Interim Chair

e. john.kelly@atomodiagnostics.com

p. +61 401 922 279

This announcement was authorised by the Board.

About Atomo



Atomo is an Australian-headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market.

Atomo's unique patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has successfully commercialised a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases including HIV, Active Syphilis, viral vs bacterial differentiation, as well as the early detection of pregnancy.

See more at www.atomodiagnostics.com